Improved real-world glycemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes

In clinical practice LIRA was associated with significantly greater reductions in A1C and improved glycemic goal attainment compared with either EXEN or SITA among adult patients with T2D (Diabetes, Obesity and Metabolism)